STRW trades 20.6% below Wall Street's consensus target of $16.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes STRW achieves its forward estimates and maintains a stable P/E multiple of 18.2x. This scenario reflects the blended consensus of 4 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of September 25, 2026, Strawberry Fields REIT, Inc. (STRW) has a Wall Street consensus price target of $16.00, based on estimates from 4 covering analysts. With the stock currently trading at $13.27, this represents a potential upside of +20.6%. The company has a market capitalization of $178M.
Analyst price targets range from a low of $16.00 to a high of $16.00, representing a 0% spread in expectations. The median target of $16.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 2 analysts rating the stock as a Buy or Strong Buy,2 rating it Hold, and 0 rating it Sell or Strong Sell. The positive sentiment balance indicates moderate optimism about the stock prospects.
From a valuation perspective, STRW trades at a trailing P/E of 22.1x and forward P/E of 18.2x. Analysts expect EPS to grow +14.6% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $80.50, with bear and bull scenarios of $50.72 and $106.07 respectively. Model confidence stands at 51/100, reflecting moderate uncertainty in projections.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 SBRASabra Health Care REIT, Inc. | $5.0B | $19.77 | $22.57 | +14.2% | Hold | 42.0x | 29 |
 CTRECareTrust REIT, Inc. | $8.8B | $37.32 | $44.43 | +19.1% | Buy | 24.3x | 19 |
 LTCLTC Properties, Inc. | $2.2B | $43.36 | $47.33 | +9.2% | Hold | 20.3x | 22 |
 GMREGlobal Medical REIT Inc. | $94M | $35.74 | $40.00 | +11.9% | Buy | 595.7x | 22 |
 OHIOmega Healthcare Investors, Inc. | $13.8B | $46.33 | $49.88 | +7.7% | Hold | 17.5x | 28 |
 NHINational Health Investors, Inc. | $3.3B | $67.16 | $79.40 | +18.2% | Hold | 17.4x | 19 |
 WELLWelltower Inc. | $168.4B | $233.64 | $258.38 | +10.6% | Buy | 82.3x | 35 |
 VTRVentas, Inc. | $42.2B | $86.83 | $99.57 | +14.7% | Buy | 149.0x | 32 |
 HRHealthcare Realty Trust Incorporated | $6.3B | $17.83 | $21.88 | +22.7% | Hold | — | 30 |
 EHCEncompass Health Corporation | $12.1B | $122.01 | $150.25 | +23.1% | Buy | 20.0x | 27 |
Quick answers to the most common questions about buying STRW stock.
The consensus Wall Street price target for STRW is $16, representing 20.6% upside from the current price of $13.27. With 4 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
STRW has a consensus rating of "Buy" based on 4 Wall Street analysts. The rating breakdown is mixed, with 2 Hold ratings making up the largest segment. The consensus 12-month price target of $16 implies 20.6% upside from current levels.
With a forward P/E of 18.2405x, STRW trades at a relatively low valuation. The consensus target of $16 implies 20.6% appreciation, suggesting meaningful undervaluation.
The most bullish Wall Street analyst has a price target of $16 for STRW, while the most conservative target is $16. The consensus of $16 represents the median expectation. Our quantitative valuation model projects a bull case target of $106 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
STRW is lightly followed, with 4 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 2 have Buy ratings, 2 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month STRW stock forecast based on 4 Wall Street analysts shows a consensus price target of $16, with estimates ranging from $16 (bear case) to $16 (bull case). The median consensus rating is "Buy". Our proprietary valuation model produces a base case fair value of $81, with bear/bull scenarios of $51/$106.
Our quantitative valuation model calculates STRW's fair value at $81 (base case), with a bear case of $51 and bull case of $106. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 51/100.
STRW trades at a forward P/E ratio of 18.2x based on next-twelve-months earnings estimates compared to a trailing P/E of 22.1x. The lower forward P/E indicates analysts expect earnings growth. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Wall Street analysts are very optimistic on STRW, with a "Buy" consensus rating and $16 price target (20.6% upside). 2 of 4 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
STRW analyst price targets range from $16 to $16, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $16 consensus represents the middle ground. Our model's $51-$106 range provides an independent fundamental perspective.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.